Home/Pipeline/Active Clinical Pipeline (unspecified)

Active Clinical Pipeline (unspecified)

Musculoskeletal repair, tissue rejuvenation, advanced healing

Not SpecifiedActive

Key Facts

Indication
Musculoskeletal repair, tissue rejuvenation, advanced healing
Phase
Not Specified
Status
Active
Company

About Skye Biologics

Skye Biologics is a vertically integrated, private biotechnology company pioneering regenerative therapies based on its proprietary extracellular matrix (ECM) preservation technology. It currently commercializes a range of tissue allograft products for advanced wound care, surgical, and ocular applications through its sister tissue bank, while actively developing a clinical pipeline aimed at repairing musculoskeletal injuries and degenerative conditions. The company targets a massive market opportunity, aiming to address a $100+ billion healthcare spend by providing biologics that enhance healing, reduce complications, and lower long-term treatment costs. With a foundation in human placental tissue processing, Skye seeks to 'hack' the healing loop to restore tissue function across multiple high-need specialties.

View full company profile